<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266499</url>
  </required_header>
  <id_info>
    <org_study_id>KPCCTIL</org_study_id>
    <nct_id>NCT01266499</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).</brief_title>
  <official_title>A Randomized Open Label Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Klebsiella pneumonia, inhabitant of the digestive tract, is a frequent nosocomial pathogen.
      It is currently the fourth most common cause of pneumonia and fifth most common cause of
      bacteremia in intensive care patients (1-3).

      The aim of the present randomized controlled trial is to assess the efficacy of
      non-absorbable oral antibiotics in the eradication of the KPC carrier state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The specific measure that will be used to determine the effect of the intervention(s): eradication rate (%).</measure>
    <time_frame>twice a week</time_frame>
    <description>- Is this outcome measure assessing a safety issue? Select: no</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia</condition>
  <arm_group>
    <arm_group_label>Group 1: will receive PO Garamycin 80mg x 4/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive PO Garamycin 80mg x 4/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : will receive PO Colistin (Polymyxin E) 100mg x 4/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: will receive both medications</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: will not receive PO treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistin (Polymyxin E) 100mg x 4/d</intervention_name>
    <description>Colistin (Polymyxin E) 100mg x 4/d</description>
    <arm_group_label>Group 2 : will receive PO Colistin (Polymyxin E) 100mg x 4/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>both medications</intervention_name>
    <description>PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d</description>
    <arm_group_label>Group 3: will receive both medications</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>will not receive PO treatment</intervention_name>
    <description>will not receive PO treatment - will receive plecebo treatment</description>
    <arm_group_label>Group 4: will not receive PO treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PO Garamycin 80mg x 4/d</intervention_name>
    <description>PO Garamycin 80mg x 4/d</description>
    <arm_group_label>Group 1: will receive PO Garamycin 80mg x 4/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria

               1. Patient identified as a KPC carrier.

               2. Patient capable to understand and sign informed consent

               3. Age &gt; 18

               4. Patient capable to receive oral medication

        Exclusion Criteria:

          -  Exclusion Criteria:

               1. Patient unable to sign informed consent

               2. Age â‰¤ 18

               3. Pregnant/lactating female

               4. Patient not expected to survive &gt; 2 weeks.

               5. Patient unable or not allowed to receive oral medications

               6. A known allergy to study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsila Zuckerman, DR</last_name>
    <role>Principal Investigator</role>
    <affiliation>rambam mc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ILANA OREN, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Site Sub Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob M Rowe, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Site Sub-Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>RENATO FINKELSTEIN, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Site Sub-Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norberto Krivoy, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Site Sub-Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HANA Shprecher, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Site Sub-Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noam Benyamini, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Site Sub-Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salim Hadad, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Site Sub-Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ami Neuberger, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Site Sub-Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eyal Braun, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Site Sub-Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayelet Raz, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Site Sub-Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam Mc</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>1. Center for Disease control and prevention. National Nosocomial Infections Surveillance 9NNIS0 System report, data summary from January 1992 through June 2003. Am J Infect Control 2003:31:481-98 2. Woodford N, Tierno PM Jr, Young K, Tysall L, Palepou MF, Ward E, Painter RE, Suber DF, Shungu D, Silver LL, Inglima K, Kornblum J, Livermore DM. Antimicrobial Agents Chemother. Outbreak of Klebsiella pneumonia producing a new carbapenem-hydrolyzing class a beta-lactamase, KPC-3, in a New York Medical Center.2004;48(12):4793-9. 3. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ, Brooks S, Cebular S, Quale J Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis. 2004 1;39(1):55-60.</citation>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>rambam68</investigator_full_name>
    <investigator_title>prof</investigator_title>
  </responsible_party>
  <keyword>Klebsiella , pneumonia, carbapenem-hydrolyzing lactamase, carbapenem-resistant Klebsiella (KPC), eradication,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Klebsiella Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Colistin</mesh_term>
    <mesh_term>Polymyxins</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

